(IN BRIEF) Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has received accelerated approval in China for patients with advanced NSCLC carrying HER2 mutations who have progressed after prior therapy. The approval is supported by Beamion-LUNG 1 data, which showed a 71% objective … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged AACR 2025, Beamion-LUNG 1, Beamion-LUNG 2, Boehringer Ingelheim, breakthrough therapy designation, CHINA, HER2 mutations, HERNEXEOS, New England Journal of Medicine, NMPA approval, non-small cell lung cancer, NSCLC, oncology, partnership, Shashank Deshpande, targeted therapy, tyrosine kinase inhibitor, Wu Yilong, zongertinib
Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating COVID-19 in addition to other diseases for which no therapeutic solutions are available (PRESS RELEASE) PARIS, 30-Nov-2020 — /EuropaWire/ — … Read the full press release
Posted in Banks, European Union, Financial, France, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Small Business
Tagged 3CL protease, AB Science SA, Alain Moussy, Ambroise Fayolle, anti-inflammatory, antiviral, chemotherapy, COVID-19, COVID-19 treatment, EIB, European Commission, European Fund for Strategic Investments, European Investment Bank, European Union, financing, health crisis, Horizon 2020, immunotherapeutic, inflammatory disease, innovationm, InnovFin, investments, kinase inhibitors, kinases, loan, macrophages, masitinib, microglia, neurological diseases, oncology, PKIs, RESEARCH, SARS-CoV-2, tyrosine kinase inhibitor
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?